Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma

Table 2 The differences of treatment outcomes between CCRT and IMRT-SIB RT alone

Items	LC		P	OS		P	DFS		P	DMFS		P
	CCRT	RT		CCRT	RT		CCRT	RT		CCRT	RT
Gender			0.13			0.30			0.1			0.30
Male	77.9	89.9		70.2	77.8		62.9	72.3		79.9	81.4
Female	93.4	92.9		81.0	89.0		70.0	79.7		81.9	91.3
Age			0.09			0.23			0.08			0.24
≤46	87.2	94.8		73.7	90.2		68.5	79.7		77.6	90.2
>46	72.7	86.3		69.2	71.3		57.7	68.3		81.2	80.9
T3	89.2	92.4	0.93	69.3	84.0	0.45	63.2	68.4	0.31	77.4	81.9	0.82
T4	54.4	76.4	0.25	66.2	67.8	0.59	41.5	64.5	0.15	77.1	91.3	0.08
N0-1	73.4	84.0	0.85	72.2	76.7	0.35	51.5	82.9	0.09	67.3	96.9	0.02
N2-3	81.8	93.5	0.05	71.5	80.4	0.36	65.4	71.6	0.24	81.7	81.8	0.93
III	91.9	95.6	0.35	84.2	88.3	0.94	77.5	80.1	0.57	89.0	86.1	0.77
IV	63.8	63.6	0.352	54.3	71.5	0.24	43.6	61.3	0.15	64.8	86.3	0.12
IVA	47.1	78.6	0.11	62.2	69.2	0.43	34.3	74.7	0.01	68.1	95.5	0.03
IVB	84.0	64.0	0.55	50.0	73.9	0.41	55.6	45.0	0.62	62.5	73.1	0.86
Whole group	80.6	90.8	0.10	71.7	83.2	0.20	63.9	74.6	0.07	79.6	86.0	0.27

LC: Local control; OS: Overall survival; DFS: Disease-free survival; DMFS: Distant metastasis-free survival; RT: IMRT-SIB alone; CCRT: Concurrent chemoradiotherapy.

ISSN: 1748-717X